A cost-effectiveness analysis of genetic testing of the DRD2 Taq1A polymorphism to aid treatment choice for smoking cessation

Nicotine and Tobacco Research

Volumn 10, Issue 1, 2008, Pages 231-240

  Welton, Nicky J ^a   Johnstone, Elaine C ^b   David, Sean P ^c   Munafò, Marcus R ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c Brown University Center for Primary Care and Prevention   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; DNA POLYMERASE TAQ1A; DOPAMINE 2 RECEPTOR; NICOTINE DERIVATIVE; TAQ POLYMERASE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; GENETIC POLYMORPHISM; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; HUMAN; NICOTINE REPLACEMENT THERAPY; PATIENT COUNSELING; PREDICTION; PRESCRIPTION; PRIORITY JOURNAL; SMOKING CESSATION; STANDARDIZATION; STRATEGIC PLANNING; TOBACCO DEPENDENCE; TREATMENT RESPONSE;

ALLELES; BUPROPION; COMBINED MODALITY THERAPY; COST OF ILLNESS; COST-BENEFIT ANALYSIS; COUNSELING; DOPAMINE UPTAKE INHIBITORS; GENETIC SCREENING; HUMANS; MODELS, ECONOMIC; NICOTINE; POLYMORPHISM, GENETIC; RECEPTORS, DOPAMINE D2; SMOKING; SMOKING CESSATION;

EID: 38149011459     PISSN: 14622203     EISSN: 1469994X     Source Type: Journal    
DOI: 10.1080/14622200701767761     Document Type: Article

References (32)

1. Ades, A. E. and Sutton, A. J. (2005) Multiparameter evidence synthesis in epidemiology and medical decision-making: Current approaches. Journal of the Royal Statistical Society A, 16:1, pp. 5-35.
2. Briggs, A., Sculpher, M. and Claxton, K. (2006) Decision modelling for health economic evaluation, Oxford University Press, Oxford, U.K.
3. Cooper, N. J., Sutton, A. J., Abrams, K. R., Turner, D. and Wailoo, A. (2004) Comprehensive decision analytical modelling in economic evaluation: A Bayesian approach. Health Economics, 13:3, pp. 203-226.
4. David, S. P., Brown, R. A., Papandonatos, G. D., Kahler, C. W., Lloyd-Richardson, E. E. and Munafò, M. R. (2007) Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation. Nicotine & Tobacco Research, 9, pp. 821-833.
5. Etter, J. and Stapleton, J. A. (1999) Nicotine replacement therapy for long-term smoking cessation: A meta-analysis. Tobacco Control, 15, pp. 280-285.
6. Evans, W. E. and Relling, M. V. (1999) Pharmacogenomics: Translating functional genomics into rational therapeutics. Science, 286:5439, pp. 487-491.
7. Fiore, M. C., Smith, S. S., Jorenby, D. E. and Baker, T. B. (1994) The effectiveness of the nicotine patch for smoking cessation. A meta-analysis. The Journal of the American Medical Association, 271:24, pp. 1940-1947.
8. Foulds, J. (2006) The neurobiological basis for partial agonist treatment of nicotine dependence: Varenicline. International Journal of Clinical Practice, 60:5, pp. 571-576.
9. Hughes, J., Stead, L. and Lancaster, T. (2004) Antidepressants for smoking cessation. Cochrane Database of Systematic Reviews, 4, p. CD000031.
10. Johnstone, E. C., Yudkin, P. L., Hey, K., Roberts, S. J., Welch, S. J. and Murphy, M. F. (2004) Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch. Pharmacogenetics, 14:2, pp. 83-90.
11. Lerman, C. and Niaura, R. (2002) Applying genetic approaches to the treatment of nicotine dependence. Oncogene, 21:48, pp. 7412-7420.
12. Lerman, C., Shields, P. G., Wileyto, E. P., Audrain, J., Hawk, Jr. and Pinto, A. (2003) Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial. Health Psychology, 22:5, pp. 541-548.
13. Lerman, C., Shields, P. G., Wileyto, E. P., Audrain, J., Pinto, A. and Hawk, L. (2002) Pharmacogenetic investigation of smoking cessation treatment. Pharmacogenetics, 12:8, pp. 627-634.
14. Lerman, C., Wileyto, E. P., Patterson, F., Rukstalis, M., Audrain-McGovern, J. and Restine, S. (2004) The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial. Pharmacogenomics Journal, 4:3, pp. 184-192.
15. Minelli, C., Thompson, J. R., Tobin, M. D. and Abrams, K. R. (2004) An integrated approach to the meta-analysis of genetic association studies using Mendelian randomization. American Journal of Epidemiology, 160:5, pp. 445-452.
16. Munafò, M. R., Johnstone, E. C., Wileyto, E. P., Shields, P. G., Elliot, K. M. and Lerman, C. (2006) Lack of association of 5-HTTLPR genotype with smoking cessation in a nicotine replacement therapy randomized trial. Cancer Epidemiology, Biomarkers, and Prevention, 15:2, pp. 398-400.
17. Munafò, M. R., Lerman, C., Niaura, R., Shields, A. E. and Swan, G. E. (2005) Smoking cessation treatment: Pharmacogenetic assessment. Current Opinion in Molecular Therapeutics, 7:3, pp. 202-208.
18. Munafò, M. R., Shields, A. E., Berrettini, W. H., Patterson, F. and Lerman, C. (2005) Pharmacogenetics and nicotine addiction treatment. Pharmacogenomics, 6:3, pp. 211-223.
19. National Institute for Clinical Excellence (2002) Guidelines on the use of nicotine replacement therapy and bupropion for smoking cessation, Author, London
20. Neville, M. J., Johnstone, E. C. and Walton, R. T. (2004) Identification and characterization of ANKK1: A novel kinase gene closely linked to DRD2 on chromosome band 11q23.1. Human Mutatation, 23:6, pp. 540-545.
21. Nielsen, K. and Fiore, M. C. (2000) Cost-benefit analysis of sustained-release bupropion, nicotine patch, or both for smoking cessation. Preventive Medicine, 30:3, pp. 209-216.
22. Poolsup, N., Po, A. Li Wan and Knight, T. L. (2000) Pharmacogenetics and psychopharmacotherapy. Journal of Clinical Pharmacy and Therapeutics, 25:3, pp. 197-220.
23. Raiffa, H. and Schaiffer, R. (1967) Applied statistical decision theory, Wiley Interscience, New York
24. Salanti, G., Higgins, J. P. T. and White, I. R. (2006) Bayesian synthesis of epidemiological evidence with different combinations of exposure groups: Application to a gene-gene-environment interaction. Statistics in Medicine, 25, pp. 4147-4163.
25. Scharf, D. and Shiffman, S. (2004) Are there gender differences in smoking cessation, with and without bupropion? Pooled- and meta-analyses of clinical trials of Bupropion SR. Addiction, 99:11, pp. 1462-1469.
26. Silagy, C., Lancaster, T., Stead, L., Mant, D. and Fowler, G. (2004) Nicotine replacement therapy for smoking cessation. Cochrane Database of Systematic Reviews, 3, p. CD000146.
27. Song, F., Raftery, J., Aveyard, P., Hyde, C., Barton, P. and Woolacott, N. (2002) Cost-effectiveness of pharmacological interventions for smoking cessation: A literature review and a decision analytic analysis. Medical Decision Making, 22:5, pp. S26-S37.
28. Swan, G. E., Valdes, A. M., Ring, H. Z., Khroyan, T. V., Jack, L. M. and Ton, C. C. (2005) Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR. Pharmacogenomics Journal, 5:1, pp. 21-29.
29. Trikalinos, T. A., Ntzani, E. E., Contopoulos-Ioannidis, D. G. and Ioannidis, J. P. (2004) Establishment of genetic associations for complex diseases is independent of early study findings. European Journal of Human Genetics, 12:9, pp. 762-769.
30. Woolacott, N. F., Jones, L., Forbes, C. A., Mather, L. C., Sowden, A. J. and Song, F. J. (2002) The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: A systematic review and economic evaluation. Health Technology Assessment, 6:16, pp. 1-245.
31. Wright, A. J., Weinman, J. and Marteau, T. M. (2003) The impact of learning of a genetic predisposition to nicotine dependence: An analogue study. Tobacco Control, 12:2, pp. 227-230.
32. Yudkin, P., Munafò, M., Hey, K., Roberts, S., Welch, S. and Johnstone, E. (2004) Effectiveness of nicotine patches in relation to genotype in women versus men: Randomised controlled trial. British Medical Journal, 328:7446, pp. 989-990.